GHB

Discovery

GHB was first synthesized in 1874, but systematic investigation began only when French biochemist Henri Laborit explored it in 1960 as a blood-brain barrier-permeable structural analog of GABA.^[2] Laborit's goal was to study inhibitory neurotransmission directly in the brain — GABA itself cannot cross the barrier. Early clinical work tested GHB as an intravenous anesthetic, a model for absence seizures, and a potential treatment for narcolepsy and alcohol dependence.^[11]

Clinical and cultural significance

During the 1980s, GHB entered American health food stores as a bodybuilding and sleep supplement, driven by evidence that bedtime doses doubled growth hormone secretion via slow-wave sleep promotion.^[12] Recreational use for euphoric and sedative effects expanded through the 1990s,^[11] and GHB gained infamy as a drug-facilitated sexual assault agent — its colorless, near-odorless liquid form and amnesia-producing properties made covert administration difficult to detect. In the United Kingdom, GHB was designated a Class C controlled substance in 2003.^[13]

Prohibition and modern use

The Hillory J. Farias and Samantha Reid Date-Rape Drug prohibition Act of 2000 placed illicit GHB on US Schedule I,^[14] while sodium oxybate (Xyrem) received FDA approval in 2002 for narcolepsy under a unique Schedule III exception with mandatory risk management.^[2][3][15] In Italy and Austria, sodium oxybate (Alcover) has been approved since the 1990s for alcohol withdrawal and dependence maintenance.^[16][17] Low-sodium oxybate (Xywav) was approved for narcolepsy in 2020 and idiopathic hypersomnia in 2021.^[18]

Structure

4-Hydroxybutanoic acid (GHB) is a short-chain hydroxy acid and structural analog of the inhibitory neurotransmitter GABA. The molecule consists of a four-carbon aliphatic chain bearing a terminal hydroxyl group and a carboxylic acid, differing from GABA only in the substitution of the amino group at C-4 with a hydroxyl group. This substitution confers blood-brain barrier permeability that GABA itself lacks — the property that motivated Laborit's original interest in the compound.

Stereochemistry

GHB is achiral — the molecule contains no stereocenters. The endogenous and exogenous forms are chemically identical.

Physical properties

The free acid is a hygroscopic solid at room temperature. The sodium salt (sodium oxybate) is a white crystalline powder, highly water-soluble due to its dual polar functional groups. GHB does not undergo significant plasma protein binding.^[5] In both clinical and illicit contexts, GHB is typically encountered as an aqueous solution or as the sodium salt.

Prodrugs and precursors

Two widely available industrial chemicals serve as GHB prodrugs: γ-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). GBL is rapidly hydrolyzed to GHB by peripheral lactonases (half-life approximately one minute), while 1,4-BD is converted via alcohol dehydrogenase and aldehyde dehydrogenase pathways.^[19] Neither precursor is scheduled under the UN Convention on Psychotropic Substances, creating a persistent legal gap through which pharmacologically equivalent GHB exposure remains accessible.^[19]

Mechanism of action

GHB produces its pharmacological effects primarily through GABA-B receptor agonism, though at substantially weaker potency than the prototypical GABA-B receptor agonist baclofen.^[6] GABA-B antagonists fully prevent GHB-induced sedation, hypothermia, and motor impairment in animal models,^[1] confirming this receptor as the primary mediator of its clinical and recreational effects.

A separate population of high-affinity GHB binding sites has been identified, including at α4β1δ GABA-A receptors.^[9] Attempts to replicate these effects in native brain tissue have not succeeded,^[10] and the functional significance of these sites remains unresolved.^[20]

The prevailing model holds that effects are dose-dependent^[6][19][4]: at low concentrations, high-affinity sites modulate dopamine tone and produce mild neuromodulation; at recreational and therapeutic concentrations, GABA-B activation predominates, producing sedation, muscle relaxation, and respiratory depression; at overdose concentrations, profound GABA-B agonism causes coma and potentially death.

Pharmacokinetics

GHB is taken almost exclusively by the oral route, with absorption onset within 5–45 minutes and peak plasma concentrations at 20–40 minutes.^[4][19] Plasma half-life is short, ranging from 20 to 60 minutes,^[19] and urinary excretion accounts for only 1–5% of the dose.^[4]

The defining pharmacokinetic feature is nonlinear, capacity-limited kinetics — both absorption and elimination are saturable, meaning small dose increases can produce disproportionately large plasma concentration jumps.^[5] GHB enters the brain via monocarboxylate transporter 1 (MCT1), another saturable system that compounds the nonlinear dose-response.^[21]

Metabolism proceeds through non-CYP hepatic pathways: oxidation to succinic semialdehyde, then to succinate and entry into the citric acid cycle.^[22] Valproate, salicylate, and phenylacetate inhibit this pathway, potentially elevating brain GHB levels — a clinically relevant drug interaction.^[22] Detection windows are short: approximately 6 hours in blood and 10 hours in urine.^[19]

Where it acts

Endogenous GHB is concentrated in the hippocampus, cortex, and dopaminergic structures including the striatum, frontal cortex, and ventral tegmental area.^[23] The dopaminergic system is a primary downstream target: at low concentrations, GHB suppresses dopamine release through high-affinity receptor stimulation; at higher exogenous concentrations, GABA-B activation initially suppresses dopamine neurons, but upon clearance, a rebound effect increase in dopamine release occurs — a mechanism proposed to underlie the brief euphoric phase that precedes sedation.

GHB administered at bedtime robustly promotes slow-wave sleep and doubles growth hormone secretion.^[12] GABA-B-mediated inhibition of brainstem arousal nuclei — particularly the laterodorsal tegmentum and raphe nuclei — directly suppresses the ascending arousal system, producing sedation and hypnosis.^[24]

Why it matters

GHB's biphasic dopamine effects — initial suppression followed by rebound release — map onto reward circuitry models: the euphoric window may reflect the transition from tonic dopamine inhibition to phasic release as high-affinity receptors desensitize, driving the compulsive redosing observed in dependent users. Its capacity to consolidate and deepen slow-wave sleep without substantially disrupting REM architecture positions GHB as both a therapeutic agent and a pharmacological tool for probing sleep homeostasis. An active Phase 2 trial (NCT06421532) is testing whether GHB-enhanced slow-wave sleep can improve brain waste clearance through the glymphatic system.

Toxicity

Respiratory depression is the primary cause of death.^[6][19] No antidote exists — treatment is entirely supportive, focused on maintaining the airway.^[6][4] Because GHB's half-life is short (20–60 minutes), patients typically recover if the airway is protected. Aspiration from vomiting while unconscious is a significant secondary risk.

Postmortem blood concentrations in GHB deaths averaged 637 mg/L but ranged from 30 to 9,200 mg/L,^[26] reflecting extreme individual variability driven by tolerance, co-ingested substances, and metabolic differences.

Psychological risks

The primary acute psychological risk is amnesia — memory suppression occurs at recreational doses and defines much of the GHB experience.^[27] This property underlies GHB's use in drug-facilitated sexual assault.^[28][29]

At low doses, disinhibition and impaired judgment increase risk-taking behavior, particularly in sexual contexts. GHB is a primary chemsex drug among men who have sex with men, with prevalence reaching 20% in some communities.^[13] Chemsex use is associated with increased HIV and STI transmission risk.

Psychological dependence develops with chronic use, driven by euphoria and anxiolysis. Relapse rates exceed 60% within three months of detoxification.^[30]

Tolerance and dependence

Tolerance develops within days of continuous use through GABA-B adaptation. The precise timeline has not been established in controlled studies.citation needed

Physical dependence develops with regular use and is a significant clinical concern.^[11][8][7] GHB use disorder is described as a growing health problem in several western countries, particularly the Netherlands.^[31]

Withdrawal onset is more rapid than alcohol or benzodiazepine withdrawal, with potentially rapid progression from mild to severe symptoms.^[7][8] Initial symptoms include insomnia, anxiety, and tremor, typically resolving in 3–12 days.^[11] Severe withdrawal can progress to delirium, agitation, psychosis, and seizures.

No FDA- or EMA-approved protocol for GHB withdrawal exists. Current approaches include:

• Benzodiazepines: first-line for symptom management, though inadequate for all cases^[32]
• Baclofen: a GABA-B agonist used as adjunct for withdrawal and relapse prevention^[33][31][13]
• Pharmaceutical GHB tapering (DeTiTap): gradual dose reduction using pharmaceutical-grade GHB, demonstrated as feasible in 23 patients in a specialist setting^[32]

Drug interactions

Alcohol combined with GHB produces additive or synergistic respiratory depression — alcohol enhances GABAergic tone broadly while GHB activates GABA-B receptors specifically.^[4][19]

Opioids (including fentanyl, heroin, methadone, and others) produce additive respiratory depression through separate mechanisms (μ-opioid vs. GABA-B).^[27] This combination is associated with coma and death.

Baclofen combined with GHB produces synergistic GABA-B activation. While baclofen is used therapeutically for GHB dependence under medical supervision,^[13] unsupervised combination carries lethal risk.

GBL and 1,4-BD are GHB prodrugs — combining any of these with GHB effectively constitutes overdose.^[19]

Stimulants (amphetamines, cocaine, MDMA) are frequently combined with GHB in chemsex contexts.^[34] The combination is not directly lethal at recreational doses, but stimulants mask GHB's sedative effects, encouraging redosing that dramatically increases overdose risk when the stimulant wears off.

Dissociatives (ketamine, PCP) combined with GHB are flagged as lethal-severity interactions in harm reduction databases. The basis — additive CNS depression from NMDA antagonism plus GABA-B agonism — is plausible, though specific case reports for these combinations were not identified.safety citation needed

Valproate, salicylate, and phenylacetate inhibit GHB metabolism, potentially elevating brain GHB levels.^[22]

HIV protease inhibitors (cobicistat, ritonavir) can dramatically elevate GHB plasma concentrations — a recognized safety concern in HIV patients using chemsex GHB/GBL.citation needed

Contraindications

Concurrent CNS depressant use (alcohol, opioids, benzodiazepines, barbiturates, ketamine) is an absolute contraindication due to lethal additive respiratory depression.^[4][19][27]

Concurrent GBL or 1,4-BD use effectively constitutes double-dosing and is an absolute contraindication.^[19]

Succinic semialdehyde dehydrogenase (SSADH) deficiency: In this rare metabolic disorder, endogenous GHB already accumulates to dangerous levels; exogenous administration is absolutely contraindicated.

Pregnancy: No safety data exist. A single case report describes withdrawal management in a pregnant patient.^[35] Use in pregnancy is contraindicated.

Respiratory compromise: Any condition impairing breathing (COPD, sleep apnea, respiratory muscle weakness) increases the risk of GHB-induced respiratory depression.

Patients on valproate or other GHB metabolism inhibitors: Enhanced effects due to impaired metabolism represent a relative contraindication.^[22]

GHB occupies an unusual regulatory position, simultaneously classified as a Schedule I controlled substance (illicit use) and a Schedule III prescription medication (pharmaceutical sodium oxybate) in the United States — a bifurcated arrangement unique in US drug policy. Internationally, GHB is controlled under Schedule IV of the UN Convention on Psychotropic Substances (2001). The prodrugs GBL and 1,4-BD remain unscheduled in most jurisdictions, creating a persistent regulatory gap through which pharmacologically equivalent GHB exposure remains accessible.^[19]

The unscheduled status of GBL and 1,4-BD under the UN Convention means these GHB prodrugs remain legally available as industrial solvents in most jurisdictions, though some countries have enacted domestic controls on their sale for human consumption.